Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P H Cottu

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Pathologie-Biologie|September 2, 2003
[Breast cancer in young women: problem and questions]M Espié, P H Cottu
Gynecologie, Obstetrique & Fertilite|March 6, 2002
[Adjuvant treatment for breast cancer. Results of the consensus conference of Saint-Gall (February 2001)]M Espié, P H Cottu
Bulletin Du Cancer|December 28, 1999
[Chemoprevention of breast cancer: what to expect after Eurocancer 1999?]P H Cottu, M Espié
La Revue Du Praticien|June 1, 1997
[Second line treatments of cancers of the ovary]J M Extra, P H Cottu
Gynecologie, Obstetrique & Fertilite|June 5, 2002
[It is possible to prescribe a hormonal replacement therapy for a woman with proliferative mastopathy with atypia]M Espié, C Cuvier, F Perret, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|June 16, 2009
[Locally advanced (neglected) breast cancer: the reality? Relevance of two cases and reflection how to optimise the multidisciplinary approach]L Monnier, C Even, P H Cottu, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Prospects with docetaxel in the treatment of patients with breast cancerM Marty, J M Extra, P H Cottu, et al.
Oncology|August 7, 1999
Optimizing chemotherapy for patients with advanced breast cancerM Marty, M Espie, P H Cottu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2011
Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomasM J Rodrigues, L Albiges-Sauvin, J Wassermann, et al.
Journal of Wound Care|November 10, 2011
Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapyP H Cottu, V Fourchotte, A Vincent-Salomon, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Pathologie-Biologie|September 2, 2003
[Breast cancer in young women: problem and questions]M Espié, P H Cottu
Gynecologie, Obstetrique & Fertilite|March 6, 2002
[Adjuvant treatment for breast cancer. Results of the consensus conference of Saint-Gall (February 2001)]M Espié, P H Cottu
Bulletin Du Cancer|December 28, 1999
[Chemoprevention of breast cancer: what to expect after Eurocancer 1999?]P H Cottu, M Espié
La Revue Du Praticien|June 1, 1997
[Second line treatments of cancers of the ovary]J M Extra, P H Cottu
Gynecologie, Obstetrique & Fertilite|June 5, 2002
[It is possible to prescribe a hormonal replacement therapy for a woman with proliferative mastopathy with atypia]M Espié, C Cuvier, F Perret, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|June 16, 2009
[Locally advanced (neglected) breast cancer: the reality? Relevance of two cases and reflection how to optimise the multidisciplinary approach]L Monnier, C Even, P H Cottu, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Prospects with docetaxel in the treatment of patients with breast cancerM Marty, J M Extra, P H Cottu, et al.
Oncology|August 7, 1999
Optimizing chemotherapy for patients with advanced breast cancerM Marty, M Espie, P H Cottu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2011
Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomasM J Rodrigues, L Albiges-Sauvin, J Wassermann, et al.
Journal of Wound Care|November 10, 2011
Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapyP H Cottu, V Fourchotte, A Vincent-Salomon, et al.
Pageof 4